Koen van Rhee
Promovendus / gast
- Naam
- K.P. van Rhee MSc
- Telefoon
- 071 5272727
- k.p.van.rhee@lacdr.leidenuniv.nl
- ORCID iD
- 0000-0001-9195-9783
Promovendus / gast
- Wiskunde en Natuurwetenschappen
- Leiden Academic Centre for Drug Research
- LACDR/Pharmacology
- Rhee K.P. van, Knibbe C.A.J., Linden P.D. van der & Brüggemann R.J.M. (2024), Patients with obesity should be recognised as a special patient population during drug development of antibacterial and antifungal agents: a Call to Action, Clinical Pharmacokinetics 63: 1-12.
- Rhee K.P. van, Brüggemann R.J.M., Roberts J.A., Sjövall F, Hest R.M. van, Elbers P.W.G., Abdulla A., Linden P.D. van der & Knibbe C.A.J. (2024), Pooled population pharmacokinetic analysis and dose recommendations for ciprofloxacin in intensive care unit patients with obesity, The Journal of Clinical Pharmacology : .
- Rhee K.P. van, Smit C., Wasmann R.E., Linden P.D. van der, Wiezer R., Dongen E.P. A. van, Krekels E.H.J., Brüggemann R.J.M. & Knibbe C.A.J. (2022), Ciprofloxacin pharmacokinetics after oral and intravenous administration in (morbidly) obese and non-obese individuals: a prospective clinical study, Clinical Pharmacokinetics 61(8): 1167-1175.
- Rhee K.P. van, Vroom S.L. de, Hest R.M. van, Linden P.D. van der, Tonino S.H., Molendijk E., Mathot R.A.A., Blijlevens N.M.A., Knibbe C.A.J., Bruggemann R.J.M. & Geerlings S.E. (2022), Impact of mucositis on oral bioavailability and systemic exposure of ciprofloxacin Gram-negative infection prophylaxis in patients with haematological malignancies, Journal of Antimicrobial Chemotherapy 77(11): 3069-3076.
- Chen L., Rhee K.P. van, Wasmann R.E., Krekels E.H.J., Wiezer M.J., Dongen E.P.A., Verweij P.E., Linden P.D., Bruggemann R.J. & Knibbe C.A.J. (2022), Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults, Journal of Antimicrobial Chemotherapy 77(8): 2217-2226.